MAIN PROGRAM

8.30-10.00 Session III:

(Paul Bergeron)

8.30-9.00: Complementary roles of spatially restricted and ontogenically distinct lung macrophages during sepsis-trained immunity
Pr Antoine Roquilly
Nantes University, FR

9.00-9.30: Blocking IL-18BP improves tumour control by radiotherapy
Anne-Gaëlle Goubet
University of Geneva, Switzerland

9.30-10.00: Association of immunotherapy and radiotherapy in head and neck squamous cell carcinoma
Dr Yungan Tao
Gustave Roussy, FR 

10.00-10.30 Coffee break and exhibition

10.30-12.30 Session IV:

 (Michele Mondini)

10.30-11.00: Unraveling the Complexity of Cancer Ecosystems Following Therapeutic Intervention
Pr Johanna Joyce
University of Lausanne, SW

11.00-11.30: Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer
Dr Fatima Mechta-Grigoriou
Institut Curie, FR

11.30-12.00: Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1
Dr Monica Olcina
University of Oxford, UK

12.00-12.30: Microbiota-Primed Fibroblasts Contribute to Radiotherapy-Induced Lung Metastasis Progression
Dr András PIFFKÓ
University Medical Center Hamburg-Eppendorf, G

12.30-14.00 Lunch break and exhibition

14.00-16.00 Session V:

(Marco Moreira)

14.00-14.30: Deciphering the dialogue between irradiated cancer cells and dendritic cells to improve anti-tumor immune responses
Pr Sandra Demaria
Weill Cornell Medicine, USA

14.30-15.00: Epigenetic, transcriptomic and genetic analyses of HR+/HER2- primary and metastatic breast cancer reveals heterogeneous mechanisms of endocrine therapy resistance
Dr Sergey Nikolaev
Gustave Roussy, FR 

15.00-15.30: STING agonism during adjuvant immunotherapy for radiocurable cancers
Pr Kevin Harrington
ICR, UK 

15.30-16.00: Micronuclei induced by radiation, replication stress, or chromosome segregation errors do not activate cGAS-STING
Dr Crispin Hiley
UCL Cancer Institute

16.00-16.30 coffee break and exhibition

16.30-18.00 Session VI:

 (Marie Morfouace)

16.30-17.00: Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Dr Jerome Galon
Cordeliers Research Center, FR

17.00-17.30: Low-dose ionizing γ-radiation elicits the extrusion of neutrophil extracellular traps
Pr Ignacio Melero
Clinica Universidad de Navarra, S

17.30-18.00: New immune-based approaches in the clinic
Pr Fabrice Barlesi
Gustave Roussy, FR 

18.00-18.30: NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity
Dr Janna Heide
University of Chicago, USA

20.00-00.00

8.30-10.0    Session VII:

 (Marine Fidelle/Carolina Alves Costa Silva)

8.30-9.00: Biomarker-Guided Selection for FLASH and Low-Dose Immunomodulation,
Dr Fernanda Herrera
CHUV, SW

9.00-9.30: Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease
Pr Martin Pruschy
University Hospital Zurich

9.30-10.00: Tumour-immune microenvironment delineates the evolutionary trajectories of distinct phenotypes of locoregionally-advanced EBV-positive nasopharyngeal carcinoma
Dr Melvin Chua Lee Kiang
Duke-NUS Medical School, SG

10.00-10.30 Coffee break and exhibition

10.30-12.30 Session VIII:

 (Ibrahim Bouakka)

10.30-11.00: The use of PET for assessing on-treatment changes in radiolabeled anti-PD-L1 uptake during hemoradiotherapy in NSCLC
Pr Idris Bahce
VUMC, NL

11.00-11.30: Translational frontiers and clinical opportunities of immunologically-fitted radiotherapy
Pr Eric Deutsch
Gustave Roussy, FR

11.30-12.00: Interventional Radiology For Cancer Immunotherapy: past, present and future
Pr Lambros Tselikas
Gustave Roussy, FR

12.00-12.30:  LPreserving the immune system in radiotherapy: modelling and AI tools
Dr Charlotte Robert
Gustave Roussy, FR

12.30-14.00 Lunch break and exhibition

14.00-16.00 Session IX:

 (Pierre-Antoine Laurent)

14.00-14.30: Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality
Pr Laurence Zitvogel
Gustave Roussy, FR

14.30-15.00: Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control
Dr Maria Esperanza Rodriguez Ruiz
Clinica Universidad de Navarra, S

15.00-15.30: Emerging evidence for adapting radiotherapy to immunotherapy
Pr Silvia Formenti
Weill Cornell Medicine, USA

15.30-16.00: Targeting Mechanism of checkpoint resistance
Pr James Welsh
MD Anderson Cancer Center, USA

16.00-16.30 Coffee break and exhibition

16.30-18.00 Session X:

 (Lydia Meziani)

16.30-17.00: Nuclear Medicine at the era of AI and Precision Oncology
Dr Desirée Deandreis
Gustave Roussy, FR

17.00-17.30: PET Imaging of PD-L1 Occupancy for Preclinical Assessment of the Efficacy of Combined Anti-PD-L1 Immunotherapy and Targeted Therapy
Dr Charles Truillet
CEA, FR

17.30-18.00:  PD-1 blockade enhances therapeutic effects of anti-CEA 177Lu-DOTA-M5A in colorectal cancer CEA-transgenic mice
Dr Tabassom Mohajershojai
Karolinska Institute, STBD

20.00-00.00 FACULTY DINNER